Ran Abuhasira

Dr. Ran Abuhasira

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
RARan Abuhasira
Ran Abuhasira
LSLiat Shbiro
Liat Shbiro
YLYuval Landschaft
Yuval Landschaft

1 March 2018 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
RARan Abuhasira
Ran Abuhasira
LSLihi Bar-Lev Schleider
Lihi Bar-Lev Schleider
RMRaphael Mechoulam
Raphael Mechoulam
VNVictor Novack
Victor Novack

1 August 2021 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
ASArik Segal
Arik Segal
YZYair Zlotnik
Yair Zlotnik
KMKeren Moyal-Atias
Keren Moyal-Atias
RARan Abuhasira
Ran Abuhasira
GIGal Ifergane
Gal Ifergane

1 November 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RARan Abuhasira
Ran Abuhasira
ARAddie Ron
Addie Ron
ISInbal Sikorin
Inbal Sikorin
VNVictor Novack
Victor Novack
Older adults may benefit from cannabis treatment for various symptoms such as chronic pain, sleep difficulties, and others, that are not adequately controlled with evidence-based therapies. However, currently, there is a dearth of evidence about the efficacy and safety of cannabis treatment for these patients. This article aims to present a pragmatic treatment protocol for medical cannabis in older adults. We followed consecutive patients above 65 years of age prospectively who were treated with medical cannabis from April 2017 to October 2018. The outcomes included treatment adherence, global assessment of efficacy and adverse events after six months of treatment. During the study period, 184 patients began cannabis treatment, 63.6% were female, and the mean age was 81.2 ± 7.5 years (median age-82). After six months of treatment, 58.1% were still using cannabis. Of these patients, 33.6% reported adverse events, the most common of which were dizziness (12.1%) and sleepiness and fatigue (11.2%). Of the respondents, 84.8% reported some degree of improvement in their general condition. Special caution is warranted in older adults due to polypharmacy, pharmacokinetic changes, nervous system impairment, and increased cardiovascular risk. Medical cannabis should still be considered carefully and individually for each patient after a risk-benefit analysis and followed by frequent monitoring for efficacy and adverse events.

2 June 2018 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
LSLihi Bar‐Lev Schleider
Lihi Bar‐Lev Schleider
RARan Abuhasira
Ran Abuhasira
VNVictor Novack
Victor Novack

1 April 2021 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
RARan Abuhasira
Ran Abuhasira
YHYosef S. Haviv
Yosef S. Haviv
MLMerav Leiba
Merav Leiba
ALAdi Leiba
Adi Leiba
LRLarisa Ryvo
Larisa Ryvo
VNVictor Novack
Victor Novack